Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,971.00
Bid: 1,971.00
Ask: 1,972.00
Change: -29.00 (-1.45%)
Spread: 1.00 (0.051%)
Open: 2,008.00
High: 2,012.00
Low: 1,958.00
Prev. Close: 2,000.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: UK Blue Chips Continue Gains Following Break

Tue, 22nd Apr 2014 16:25

LONDON (Alliance News) - UK equities closed mixed Tuesday, with large- and mid-cap stocks outperforming their smaller peers to end the day in positive territory for the third trading day in a row, as individual company news took centre stage.

Following a four-day Easter break, London's major equity indices advanced strongly on the back of a raft of merger and acquisitions activity and speculation within the pharmaceuticals sector.

Blue-chip pharmaceuticals giant GlaxoSmithKline's shares jumped significantly, closing up 4.3%, after it announced a series of strategic deals with Switzerland's Novartis AG to create an expanded consumer healthcare and vaccines franchise and to exit its oncology portfolio.

Under a three-part deal, the group, which is the fourth biggest constituent of the FTSE 100 by market capitalisation, said that it will divest its marketed oncology portfolio to Novartis for an aggregate cash consideration of USD16 billion, of which up to USD1.5 billion will be dependent on the results of its COMBI-d trial. Moreover, it will acquire Novartis' global vaccines business, excluding influenza vaccines, for an initial cash consideration of USD5.25 billion, with subsequent potential milestone payments of up to USD1.8 billion and ongoing royalties.

Finally, the two companies also will create together a new consumer healthcare business with 2013 pro-forma revenues of GBP6.5 billion and with Glaxo having the majority control at 63.5%.

“Opportunities to build greater scale and combine high quality assets in vaccines and consumer healthcare are scarce," said Glaxo Chief Executive Officer Andrew Witty. "With this transaction we will substantially strengthen two of our core businesses and create significant new options to increase value for shareholders," he added.

Glaxo estimates that the transaction would increase its annual revenue by GBP1.3 billion to GBP26.9 billion, on a 2013 pro-forma basis, and fundamentally re-shape its revenue mix.

At the same time, the firm said it will return GBP4 billion to shareholders which will be delivered by means of a B share scheme.

Further lifting the FTSE 100, AstraZeneca, also one of the ten largest companies in the index by market capitalisation, closed up 6.3%. The pharma's shares rose sharply following weekend reports by The Sunday Times that US giant Pfizer Inc made USD101 billion takeover offer, which AstraZeneca rejected.

Although the report said that no talks are currently underway after AstraZeneca resisted the approach, Pfizer could return with a better offer as it sits on a huge cash hoard in overseas subsidiaries that it could utilize for a major acquisition.

“After such a long time without the kind of mega-mergers seen in telecoms and utilities, the pharmaceutical sector is seeing a surge in speculation over who will be next,” said Jasper Lawler, market analyst at CMC Markets.

FTSE 100-listed Shire and FTSE 250-listed Hikma Pharmaceuticals ended the day up 5.5% and 5.0%, respectively, as they were boosted by the news.

Overall, the FTSE 350 pharmaceuticals and biotechnology sector closed up 5.3%, as the biggest gaining sector index.

FTSE 250-constituent Worldwide Healthcare Trust, which invests in pharmaceutical and biotechnology companies and related securities in the healthcare sector, benefited from the big rise in the sector, closing up 6.0%.

M&A talk in the pharmaceutical sector is rife at the moment. Novartis has agreed to sell its animal health business to US-based Eli Lilly for about USD5.4 billion, while Allergan Inc confirmed that it has received an unsolicited proposal from Canadian drug maker Valeant Pharmaceuticals International Inc to acquire all of the outstanding shares of the company.

It was a different story in the AIM All-Share index, however, where Quindell, the second largest company in the index by market cap, closed down 50%, weighing heavily on the index.

The company, which provides expertise in software, consultancy and technology, saw its shares fall off a cliff, pulling the AIM All-Share index into the red with it, following the publication of a research report that called into question most of the company's profits. Gotham City Research LLC said that it has been unable to reconcile between 42% and 80% of the firm's profits, saying that they are suspect as they are explained by sales to related parties owned and operated by Quindell Chief Executive Robert Terry.

Quindell's shares dropped to a new low for 2014 in the immediate aftermath of the report's release, before recovering somewhat after the firm rejected Gotham City Research's assertions. Quindell said the note was "highly defamatory, deliberately misrepresentative" and that it "entirely rejects the conclusions that are made".

The FTSE 100 closed up 0.9% at 6,681.76, ensuring that it ended the day in the black for the third consecutive trading day for the first time since February. The FTSE 250 also ended the day in positive territory for the third trading day in a row, closing up 1.1% at 16,082.24. The AIM All-Share index, however, closed down 0.8% at 823.02.

In Europe, the CAC 40 in Paris and the DAX 30 in Frankfurt closed up 1.1% and 2%, respectively.

On Wall Street, at the close of the UK equity market, the DJIA and S&P 500 were up around 0.5%, while the NASDAQ Composite was up 1%.

In other individual UK equity news, FTSE 250-constituent Colt Group ended the day as the mid-cap index's biggest loser, down 10%. The telecommunications company's shares plummeted after it lowered its forecasts for 2014 earnings before interest, tax, depreciation and amortisation due to compression of its profit margins.

The group said that it now expects its 2014 EBITDA, before restructuring costs, to be between 5% and 10% below current consensus estimates of EUR325 million. It said it also expects to post restructuring costs of EUR30 million in the second half as it continues to reorganise its operations into four units and announced plans to reduce its Carrier voice business.

Colt said it plans to withdraw from around 85% of its Carrier voice contracts, which involve the carrying of voice calls for other telecommunications providers, over the next few months to release around five billion minutes per year of voice network capacity.

Colt also released results for the first quarter to end-March. It posted revenue of EUR399.8 million, up from EUR392.1 million in the previous year, but EBITDA dropped to EUR74.1 million from EUR80.5 million, hit by compressed margins as the company changed its mix of products, saw continued price pressures in its bandwidth products, and felt the affect of declines in its Enterprise voice customers.

QinetiQ Group, closing down 1.9%, was another big faller in the FTSE 250. The company's shares fell sharply after its subsidiary, QinetiQ US Holdings Inc, revealed that it had entered into a conditional agreement to sell QinetiQ Group's US Services division for an initial USD165 million deal.

The agreement, which is set to complete in the second quarter of 2014, will see the US Services division sold to The SI Organisation Inc for an initial cash consideration of USD165 million plus a potential earnout of up to USD50 million in cash, following a market testing exercise that attracted a number of interested parties, said the firm.

Vedanta Resources, on the other hand, was a big riser, closing up 2.0%. The mining company announced that the Supreme Court in India has partially lifted the ban on mining in the state of Goa, where iron ore mining operations at its subsidiary Sesa Sterlite Ltd have been suspended since 2013.

With a dearth of macroeconomic data Tuesday, there was little movement in the forex market. At the close of the UK equity market, the pound continued to trade near a multi-year high against the dollar at USD1.6831, while also trading at EUR1.3803, CHF1.4896, and JPY172.640.

In a busier day in the data calendar Wednesday, the preliminary reading of Chinese HSBC manufacturing purchasing managers index for April is released at 0145 GMT. Preliminary French Markit manufacturing and services PMI data for April are released at 0700 GMT, ahead of preliminary German Markit manufacturing PMI for April at 0728 GMT, and preliminary German Markit services PMI for April at 0730 GMT. The equivalent readings for the wider eurozone are released at 0800 GMT.

The minutes from the latest Bank of England Monetary Policy Committee meeting, which will reveal the number of members who voted to leave the UK's interest rate unchanged, the number who wanted to raise it, and a number who wanted to lower it, are released at 0830 GMT. Public sector net borrowing information for March is released at the same time.

In the US, the Mortgage Bankers Association released its MBA mortgage applications data at 1100 GMT, ahead of the preliminary Markit manufacturing PMI for April at 1345 GMT. Home sales data are published at 1400 GMT.

In the corporate calendar, in the FTSE 100, Associated British Foods releases full-year results, ARM Holdings releases first-quarter results, and Sports Direct International, Reed Elsevier, and Hammerson are joined by FTSE 250 constituents AMEC, MoneySuperMarket.com Group and Spirent Communications in releasing trading updates. Mid-cap Fenner provides half-year results.

By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
12 Apr 2023 07:52

LONDON BRIEFING: Anglo American's De Beers shines; Unite bookings up

(Alliance News) - Stocks in London were called flat on Wednesday, with the focus for the day on a US inflation reading in the afternoon, before the release of central bank meeting minutes later.

Read more
12 Apr 2023 07:18

Hikma appoints Riad Mishlawi as CEO

(Sharecast News) - Hikma Pharmaceuticals said Riad Mishlawi, president of the group's injectables business, has been appointed chief executive Officer, effective from September 1.

Read more
6 Apr 2023 09:20

LONDON BROKER RATINGS: Goldman raises Spirent to 'neutral' from 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
16 Mar 2023 15:50

UK dividends calendar - next 7 days

Friday 17 March 
JPMorgan Claverhouse Investment Trust PLCdividend payment date
Knights Group Holdings PLCdividend payment date
NCC Group PLCdividend payment date
Pershing Square Holdings Ltddividend payment date
Ruffer Investment Co Ltddividend payment date
Witan Investment Trust PLCdividend payment date
Monday 20 March 
Aquila Energy Efficiency Trust PLCdividend payment date
Essentra PLCspecial ex-dividend payment date  
Shaftesbury Capital PLCdividend payment date
Tuesday 21 March 
abrdn Asia Focus PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
Unilever PLCdividend payment date
Wednesday 22 March 
abrdn Equity Income Trust PLCdividend payment date
Thursday 23 March 
BlackRock Energy & Resources Income Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
Close Brothers Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Craneware PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Glanbia PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Hipgnosis Songs Fund Ltdex-dividend payment date
Jersey Electricity PLCdividend payment date
Nichols PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Prudential PLCex-dividend payment date
Schroders PLCex-dividend payment date
Securities Trust of Scotland PLCex-dividend payment date
Volution Group PLCex-dividend payment date
XP Power Ltdex-dividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
13 Mar 2023 09:40

LONDON BROKER RATINGS: JPMorgan cuts BAT; raises Bunzl

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Mar 2023 09:15

LONDON BROKER RATINGS: Liberum cuts National Express to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
6 Mar 2023 09:48

LONDON BROKER RATINGS: DB cuts Reckitt; Jefferies likes Tesco

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
1 Mar 2023 09:52

LONDON BROKER RATINGS: Canaccord says sell Future; Investec likes RWS

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
27 Feb 2023 09:38

Berenberg raises target price on Hikma Pharmaceuticals

(Sharecast News) - Analysts at Berenberg raised their target price on drugmaker Hikma Pharmaceuticals from 1,440.0p to 1,740.0p on Monday on the back of the group's recent trading update.

Read more
27 Feb 2023 09:26

LONDON BROKER RATINGS: Citi cuts Quilter to 'sell'; Goldman likes GSK

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
24 Feb 2023 09:37

LONDON BROKER RATINGS: SocGen cuts Burberry; BofA cuts WH Smith

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
23 Feb 2023 09:54

Hikma Pharmaceuticals profit halves in 2022 on Generics impairment

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reported a dip in annual revenue for 2022, as profit tumbled due to high inflation and adjustments regarding expectations for its Generics business.

Read more
23 Feb 2023 09:02

LONDON MARKET OPEN: Mixed open in London; Rolls-Royce up, Mondi down

(Alliance News) - Stock prices in London opened mixed on Thursday, with large-cap indices underperforming amid mixed corporate earnings.

Read more
23 Feb 2023 07:59

Competition in generics sees Hikma Pharmaceuticals's profits decline by a tenth

(Sharecast News) - Hikma Pharmaceuticals posted lower full-year profits as stiff competition in generics saw its top line growth flatten out.

Read more
23 Feb 2023 07:56

LONDON BRIEFING: WPP profit jumps in 2022; guides for further growth

(Alliance News) - Stocks in London were called to open slightly higher on Thursday, as investors were unfazed by a fairly uneventful set of policy meeting minutes from the US central bank.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.